Nanaimo-based Tilray plans to have its products available to patients and doctors in the United Kingdom in March, thanks to an agreement with a U.K.-based distribution firm. (News Bulletin file photo)

Nanaimo-based Tilray plans to have its products available to patients and doctors in the United Kingdom in March, thanks to an agreement with a U.K.-based distribution firm. (News Bulletin file photo)

Nanaimo-based Tilray announces U.K. medical cannabis distribution agreement

Agreement with distributor Grow Pharma will expand access to Tilray products

Nanaimo-based medical cannabis producer Tilray has announced an agreement with Grow Pharma to import and distribute medical cannabis products in the United Kingdom.

According to a Tilray news release Tuesday, Feb. 9, the agreement allows Tilray to provide authorized U.K. patients through Grow Pharma, a U.K. distributor that is part of the Grow Group, which is comprised of three business units: Grow Pharma, Grow Trading and Grow Biotech. Grow Pharma will work with producers of cannabis-based medicines to introduce those products in new markets, such as the U.K. and Ireland.

Brendan Kennedy, Tilray’s chief executive officer, said in the press release that the partnership provides patients in need access to high-quality medical cannabis “and is an important step in improving access in the U.K.,” adding that “Tilray will continue to advocate for reasonable patient access to medical cannabis in Europe and countries around the world.”

Tilray expects to have a range of products available to patients in the U.K. in March.

READ ALSO: Merger makes Nanaimo-based Tilray the world’s largest cannabis company

READ ALSO: Tilray medicinal-cannabis product shows promise in cancer therapy research study



photos@nanaimobulletin.com
Like us on
Facebook and follow us on Twitter

cannabis